PHARMING GROUP NV revenue breakdown overview

PHARMING GROUP NV revenue for the last year amounted to 269.92 M CHF, the most of which — 258.32 M CHF — came from its highest performing source at the moment, Recombinant Human C1 Esterase Inhibitor, the year earlier bringing 210.86 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought PHARMING GROUP NV 249.58 M CHF, and the year before that — 205.53 M CHF.